Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin resistant ovarian cancer

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2346-2350

  Xie, Ya ^a   Peng, Zheng ^a   Shi, Mingxing ^a   Ji, Mei ^a   Guo, Hongjun ^a   Shi, Huirong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cell proliferation; Cisplatin resistant ovarian cancer; Metformin; P38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; METFORMIN; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES;

EID: 84907202285     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2490     Document Type: Article

References (21)

1. Morrison J, Haldar K, Kehoe S and Lawrie TA: Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 8: CD005343, 2012.
2. Ozols RF: Treatment goals in ovarian cancer. Int J Gynecol Cancer 15: 3-11, 2005.
3. McLemore MR, Miaskowski C, Aouizerat BE, Chen LM and Dodd MJ: Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs. 32: 281-290, 2009.
4. Agarwal R and Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
5. National Comprehensive Cancer Network: Clinical Practice Guidelines™ in Oncology (version 1.2011). 2011.
6. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 123: 200-204, 2011.
7. Romero IL, McCormick A, McEwen KA, et al: Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119: 61-67, 2012.
8. Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250, 2008.
9. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13: 483-491, 2011.
10. Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71: 3196-3201, 2011.
11. Rocha GZ, Dias MM, Ropelle ER, et al: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005, 2011.
12. Xing D and Orsulic S: Modeling resistance to pathway-targeted therapy in ovarian cancer. Cell Cycle 4: 1004-1006, 2005.
13. Ohta T, Ohmichi M, Hayasaka T, et al: Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147: 1761-1769, 2006.
14. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005.
15. Kuo MT, Liu Z, Wei Y, et al: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21: 1945-1954, 2002.
16. Rattan R, Giri S, Hartmann LC and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178, 2011.
17. Xie Y, Wang YL, Yu L, et al: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126: 113-120, 2011.
18. Tseng SC, Huang YC, Chen HJ, et al: Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. Biochem Pharmacol 85: 583-594, 2013.
19. Liu H, Scholz C, Zang C, et al: Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32: 1627-1637, 2012.
20. Monteagudo S, Pérez-Martinez FC, Pérez-Carrión MD, et al: Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells. Nanomedicine (Lond.) 7: 493-506, 2012.
21. Kim HG, Hien TT, Han EH, et al: Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162: 1096-1108, 2011.